07.09.2022 - ROCKVILLE, Md., Sept. 07, 2022 (GLOBE NEWSWIRE) - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as .
45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, Md., Aug. 10, 2022 /PRNewswire/
Investegate |MaxCyte, Inc. Announcements | MaxCyte, Inc.: Total Voting Rights investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.